EMA Safety Committee confirms that COVID-19 Vaccine AstraZeneca benefits still outweigh the risks despite possible link to rare blood clots with low blood platelets.
EMA’s safety committee, PRAC, concluded its preliminary review of a signal of blood clots in people vaccinated with COVID-19 Vaccine AstraZeneca at its extraordinary meeting of 18 March 2021. The Committee confirmed that: the benefits of the vaccine in combating the still widespread threat of COVID-19 (which itself results in clotting problems and may be fatal)